Experimental brain cancer vaccine made available to patients with no other options
NCT ID NCT04802447
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This program gives certain glioblastoma patients access to SurVaxM, a drug that helps the immune system fight brain cancer. It is for patients who cannot join other trials or who have already benefited from SurVaxM in a previous study. The treatment involves four doses given two weeks apart, followed by a dose every three months for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SurVaxM (a vaccine-like drug that trains the immune system to attack cancer cells)
What this could lead to
If it works, this could offer a way to extend survival for people with glioblastoma who have few other options.
What could go wrong
This is an expanded access program, not a formal trial, so results are not proven. The drug may not work for everyone and requires repeated doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.